|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007121,
umls-concept:C0007634,
umls-concept:C0043227,
umls-concept:C0205179,
umls-concept:C0239307,
umls-concept:C0596545,
umls-concept:C0684249,
umls-concept:C1306673,
umls-concept:C1514474,
umls-concept:C1518904,
umls-concept:C1563350,
umls-concept:C1563351
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1998-3-27
|
|
pubmed:abstractText |
The European Lung Cancer Working Party has investigated prognostic factors for response, overall survival, long term survival in a population with advanced non small cell lung cancer registered in a clinical trial evaluating platinum derivatives-containing chemotherapy regimens. Various factors have been identified in multivariate analyses and were classified using RECPAM methodology. In addition to the clinical factors such as disease extent and performance status were shown, as significant predictors, rarely studied biological factors like pretherapeutic leucocyte and polynuclear levels. The obtention of an objective response to chemotherapy appeared to be a major prognostic factor for further survival.
|
|
pubmed:language |
fre
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0761-8425
|
|
pubmed:author |
pubmed-author:BerchierM CMC,
pubmed-author:BureauGG,
pubmed-author:DabouisGG,
pubmed-author:GinerVV,
pubmed-author:KlasterskyJJ,
pubmed-author:LibertPP,
pubmed-author:MichelJJ,
pubmed-author:MommenPP,
pubmed-author:PaesmansMM,
pubmed-author:SchmerberJJ,
pubmed-author:SculierJ PJP,
pubmed-author:SergyselsRR,
pubmed-author:ThiriauxJJ,
pubmed-author:Van CutsemOO
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
445-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9496602-Age Factors,
pubmed-meshheading:9496602-Antineoplastic Agents,
pubmed-meshheading:9496602-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9496602-Carboplatin,
pubmed-meshheading:9496602-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9496602-Cisplatin,
pubmed-meshheading:9496602-Clinical Trials as Topic,
pubmed-meshheading:9496602-Female,
pubmed-meshheading:9496602-Forecasting,
pubmed-meshheading:9496602-Humans,
pubmed-meshheading:9496602-Karnofsky Performance Status,
pubmed-meshheading:9496602-Leukocyte Count,
pubmed-meshheading:9496602-Lung Neoplasms,
pubmed-meshheading:9496602-Male,
pubmed-meshheading:9496602-Multicenter Studies as Topic,
pubmed-meshheading:9496602-Multivariate Analysis,
pubmed-meshheading:9496602-Neoplasm Staging,
pubmed-meshheading:9496602-Neutrophils,
pubmed-meshheading:9496602-Prognosis,
pubmed-meshheading:9496602-Registries,
pubmed-meshheading:9496602-Remission Induction,
pubmed-meshheading:9496602-Sex Factors,
pubmed-meshheading:9496602-Survival Rate,
pubmed-meshheading:9496602-Treatment Outcome
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party].
|
|
pubmed:affiliation |
Institut Jules Bordet, Bruxelles.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
